Common variable immunodeficiency (CVID), previously known as humoral immunodeficiency, includes a group of different disorders that are shared by marked reductions in the serum levels of immunoglobulins A, G, and M.
Immunoglobulin M is related to the acute immune response against infections, immunoglobulin G is related to long-term immunity and immunoglobulin A is implicated in secretory immunity; therefore, patients who have CVID are at risk of recurrent infections, impaired immune responses, such as autoimmune diseases and granulomatous disease, and malignancy. The disease belongs to a heterogenous group of immunologic disorders of unknown etiology.
Epidemiology of Pediatric CVID
CVID is a collective term that includes different disorders that all share the same features of reduced serum levels of immunoglobulins. The estimated incidence of CVID is approximately 1 per 30,000. The prevalence of CVID varies by countries. The disorder is reported to have the highest prevalence in France, Spain and the Netherlands, but to be rare in Poland.
Mortality related to CVID is correlated with the severity of the recurrent infections and the development of certain diseases related to impaired immunity; therefore, patients who develop bronchiectasis and severe lung damage, those with malignant disease and patients with autoimmune disorders have a higher mortality rate compared to patients who do not develop any of these complications.
Some possible predictive variables of reduced survival in CVID include an early age at diagnosis, lower baseline immunoglobulin G serum levels and low peripheral B cells. Additionally, patients with malignancy or autoimmune disorders have a higher mortality rate compared to those with infectious complications. Nowadays, up to 60% of patients survive more than 40 years after the diagnosis.
CVID has been reported in all ethnicities and has an equal incidence rate in both genders. While most cases are diagnosed in their twenties, up to one-third of the patients are diagnosed during childhood.
|0 – 6 months||2 – 6 years||> 6 years|
|X-linked agammaglobulinemia||IgA deficiency||Common variable immunodeficiency|
|Selective IgG deficiency|
|Hyper IgM syndrome||Hypogammaglobulinemia||Acquired disease (HIV, lupus, etc.)|
|Hyper IgE (Job syndrome)|
Pathophysiology of Pediatric CVID
Patients with CVID have immunologic disorders that are characterized by reduced serum levels of the different immunoglobulins. Most patients have pronounced reduced serum levels of immunoglobulins A and G. Immunoglobulin M serum levels are also reduced in up to 50% of the cases.
Due to reduced immunoglobulin A levels, patients are at an increased risk of recurrent bacterial infections. Patients might develop pyogenic lung infections, pneumocystis jiroveci pneumonia and mycoplasma pneumoniae atypical pneumonia. Recurrent urinary tract infections due to mycoplasma pneumoniae, septic arthritis and deep tissue abscess are also common in CVID.
Due to the impaired immunity state in CVID, patients are at risk of developing different autoimmune disorders, such as immune thrombocytopenic purpura, hemolytic anemia, rheumatoid arthritis and inflammatory bowel disease.
Most cases of CVID are sporadic, but familial autosomal dominant CVID has been described in at least 10% of the cases. Genetic testing in CVID is complicated because of the large number of possible etiologies of the disorder. Regardless, certain genetic defects have been clearly associated with CVID such as TACI, and ICOS mutations. CD19, CD81, CD20 and CD21 deficiencies have also been implicated with CVID. These genetic defects are usually linked to impaired B-cell activity, but ICOS mutations are linked to T-cell function.
Clinical Presentation of Pediatric CVID
- Patients who present with recurrent pyogenic lung and sinus infections due to Moraxella catarrhalis, streptococcus pneumoniae and staphylococcus aureus should be evaluated for possible CVID. Unusual organisms, such as pneumocystis jiroveci and fungal pneumonia, are also more common with CVID compared to healthy immune-competent children.
- Patients might present with persistent diarrhea due to giardia lamblia as it is also common with CVID.
- Patients can also develop severe herpes simplex infections, and herpes zoster eruptions are common.
- Possible presentations of autoimmune disorders due to CVID include anemia and recurrent infections due to cytopenia, recurrent bruising and petechia due to idiopathic thrombocytopenic purpura and thyroid disorders.
- Vitiligo, type 1 diabetes mellitus, psoriasis, systemic lupus erythematosus, arthritis and ulcerative colitis or Crohn’s disease are also more common in patients with CVID.
- Granulomas in the lungs, lymph nodes, skin and the gastrointestinal tract resemble sarcoidosis on histologic examination.
- The most common malignancy associated with CVID is non-Hodgkin’s lymphoma. Gastric malignancy, breast cancer, colon cancer, prostate cancer and ovarian cancer are also commonly associated with CVID.
The most important features in clinical examination of a child with CVID are the presence of lymphadenopathy and splenomegaly. Patients could also have localized signs that are specific to the infectious complication they are presenting with, i.e. crackles and reduced breath sounds in pneumonia.
|Job syndrome||X-linked agammaglobulinemia, hypogammaglobulinemia||Common variable immune deficiency|
|Extremely high levels of IgE||No immunoglobulins in blood||B-cell deficiency|
|“Coarse facies”||Male gender (x-linked recessive)||High risk of autoimmune disorders (AHA, ITP)|
|Recurrent sinopulmonary infections||Failure to thrive (x-linked agammaglobulinemia)||Higher risk for malignancy (lymphoma, gastric carcinoma)|
|Eczema||Later childhood or early adult presentation (hypogammaglobulinemia)||Later onset (average age of presentation: 26 years, but earlier possible)|
|Recurrent cellulitis||Recurrent otitis media, sinusitis, pneumonia|
|→ Treatment is supportive||→ Treat with regular IVIG infusions (every 3 weeks)||→ Treat with IVIG|
Diagnostic Workup for Pediatric CVID
Patients who present with recurrent pyogenic lung and sinus infections, autoimmune disorders and lymphoid hyperplasia should be evaluated for possible CVID.
The first diagnostic test would be to determine the levels of the different immunoglobulins, i.e. IgG, IgM, and IgA.
All patients with CVID have decreased IgG and IgA levelsbut not absent IgG and IgA. IgM levels are usually reduced, but some patients might have normal or even elevated IgM levels. Radial immunodiffusion is the preferred method for the quantification of serum immunoglobulins. Serum levels of immunoglobulins are age-dependent; therefore, age-adjusted normal values should be used whenever you try to interpret the results.
Once reduced levels of immunoglobulins are confirmed, the next question would be whether this deficiency is due to decreased synthesis or to the loss of the immunoglobulins. Patients with CVID have decreased synthesis of immunoglobulins. Determination of serum levels of the different immunoglobulins following active immunization is a possible technique to differentiate between immunoglobulins deficiency due to a loss versus impaired synthesis.
Enumeration of circulating B cells and T cells:
- Serum peripheral B cell count should also be determined as low peripheral B cell count has been associated with reduced survival in CVID. Patients with CVID can also have impaired lymphocyte response to certain antigens. Lymphocytes can be isolated from the patient’s blood and presented with different mitogens, antigens, and specific antibodies against T-cell surface molecules.The common antibodies used in immunofluorescence staining for this quantification include CD3 and CD4 for T cells and CD20 and CD21 for B cells. other non-specific antibodies include CD16, CD56 and CD57.
Complete blood count:
- A complete blood count is also indicated in CVID as it can reveal anemia which is usually hemolytic, thrombocytopenia and lymphopenia. Lymphopenia is more common in severe CVID.
Assessment of comorbid conditions for proper management:
- Patients who have CVID are at an increased risk of developing recurrent lung infections and possibly bronchiectasis. High-resolution computed tomography scanning of the lungs is indicated to exclude the presence of damaged lung architecture which is associated with reduced survival.
- The identification of the causative infective organism in a patient presenting with infectious complications of CVID should be attempted. Culture and sensitivity testing is recommended as it can help in the identification of the causative organism and guide antibiotic therapy.
- Patients with lung nodules should undergo a bronchoscopy to examine the nodule and a biopsy should be obtained. Histologic examination of the biopsy allows for the differentiation between lymphoid hyperplasia, non-Hodgkin’s lymphoma, and granulomatous lesions. The differentiation between the different types of nodules has an impact on the survival rate.
Treatment of Pediatric CVID
The most common presentation of CVID is that of infectious complications. Antibiotic and/or antifungal therapy is indicated in the treatment of infectious diseases in CVID. The choice of anti-microbial drugs should be based on the location of the infection, the most likely causative organism, and the results of culture and sensitivity testing.
Immunoglobulin replacement therapy is the mainstay treatment of CVID. Regular intravenous immunoglobulin replacement therapy is indicated and usually successful in patients with recurrent pyogenic lung and sinus infections due to CVID. Immunoglobulin replacement therapy does not influence the incidence of autoimmune or malignant disorders.
Patients who have an existing infection should be treated with appropriate antimicrobial therapy before starting immunoglobulin replacement therapy as the risk of non-anaphylactic reactions is more common in this subgroup. Possible non-anaphylactic reactions to immunoglobulin replacement therapy include headaches, chills, fever, chest tightness, myalgia, fatigue and nausea.
Patients with autoimmune disorders due to CVID might need short-term corticosteroid therapy. Patients who have lymphoid interstitial pneumonitis, an autoimmune disorder, might benefit from cyclosporine A. Patients presenting with thrombocytopenia or neutropenia should be treated with anti-CD20. Granulomatous disease in CVID responds to anti-TNF therapy (infliximab).
Finally, patients who develop deep skin abscesses or lung abscesses should undergo an incision and drainage procedure. Surgical treatment of bronchiectasis involves the resection of the affected lung lobes and might also be needed.
Selective IgA deficiency
|1. Recurrent sinopulmonary infections||Treat infections, consider IVIG|
|2. GI disorders (celiac disease, IBD)||Treat disease, consider IVIG|
|3. Autoimmune disease (lupus, JIA)||Treat disease, consider IVIG|
|4. Anaphylaxis to transfusion of blood or IVIG||Desensitize to blood products|